• Deutsch
    • English
  • English 
    • Deutsch
    • English
  • Login
Item View 
  •   Home
  • Medizin
  • Human- und Zahnmedizin
  • Item View
  •   Home
  • Medizin
  • Human- und Zahnmedizin
  • Item View
JavaScript is disabled for your browser. Some features of this site may not work without it.

Wirkung des standardisierten japanischen Kampo-Arzneipflanzenpräparates Juzentaihoto auf das Tumormikroenvironment des Pankreaskarzinoms – ein Vergleich mit Gemcitabin

Effect of the standardized Japanese Kampo Extract Juzen-taiho-to on the Tumor microenvironment in a Pancreatic cancer mouse model – a comparison to Gemcitabine

by Anna Paulina Siebel
Doctoral thesis
Date of Examination:2025-03-20
Date of issue:2025-02-24
Advisor:PD Dr. Silke Cameron
Referee:Dr. Joanna Napp
Referee:Prof. Dr. Thomas Meyer
crossref-logoPersistent Address: http://dx.doi.org/10.53846/goediss-11104

 

 

Files in this item

Name:2025_02_06_Siebel_Anna Paulina_Dissertation_...pdf
Size:36.4Mb
Format:PDF
ViewOpen

The following license files are associated with this item:


Abstract

English

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive gastrointestinal malignancies, characterized by poor prognosis and limited therapeutic success. Despite surgical resection being the sole curative approach, the high recurrence rate and late-stage diagnosis necessitate innovative therapeutic strategies. This study investigates the immunomodulatory effects of the standardized Japanese herbal medicine Juzentaihoto (JUZ) alone and in combination with gemcitabine, a standard chemotherapeutic agent, in an orthotopic pancreatic cancer mouse model and in vitro settings. The findings demonstrate that JUZ promotes M1 macrophage polarization, enhancing anti-tumor immune responses, while improving the efficacy of gemcitabine by mitigating its resistance. Additionally, JUZ significantly modulates the tumor microenvironment and cytokine expression, resulting in prolonged survival in treated groups. These results underline the potential of JUZ as an adjuvant therapy for PDAC, emphasizing the need for further molecular investigations and clinical trials to validate its application.
Keywords: Pancreatic ductal adenocarcinoma (PDAC); Kampo medicine; Juzentaihoto; Gemcitabine; orthotopic transplantation PDAC mouse model; murine KPC pancreatic tumor cells; macrophages; tumor microenvironment
Schlagwörter: Kampo Medizin; Juzentaihoto; Gemcitabin; Duktales Pankreaskarzinom; Makrophagen; Tumormikroenvironment
 

Statistik

Publish here

Browse

All of eDissFaculties & ProgramsIssue DateAuthorAdvisor & RefereeAdvisorRefereeTitlesTypeThis FacultyIssue DateAuthorAdvisor & RefereeAdvisorRefereeTitlesType

Help & Info

Publishing on eDissPDF GuideTerms of ContractFAQ

Contact Us | Impressum | Cookie Consents | Data Protection Information | Accessibility
eDiss Office - SUB Göttingen (Central Library)
Platz der Göttinger Sieben 1
Mo - Fr 10:00 – 12:00 h


Tel.: +49 (0)551 39-27809 (general inquiries)
Tel.: +49 (0)551 39-28655 (open access/parallel publications)
ediss_AT_sub.uni-goettingen.de
[Please replace "_AT_" with the "@" sign when using our email adresses.]
Göttingen State and University Library | Göttingen University
Medicine Library (Doctoral candidates of medicine only)
Robert-Koch-Str. 40
Mon – Fri 8:00 – 24:00 h
Sat - Sun 8:00 – 22:00 h
Holidays 10:00 – 20:00 h
Tel.: +49 551 39-8395 (general inquiries)
Tel.: +49 (0)551 39-28655 (open access/parallel publications)
bbmed_AT_sub.uni-goettingen.de
[Please replace "_AT_" with the "@" sign when using our email adresses.]